MET and breast cancer: In addition, c-Met phosphorylation participates in the activation of several intracellular pathways that have been involved in the promotion of epithelial–mesenchymal transition, invasiveness and drug resistance of urothelial malignant cells—the high expression of phosphorylated c-Met being a poor prognosis factor in patients with advanced BC [145].